Asia-Pacific is rapidly gaining importance as a major pillar in global life science innovation
- Speaking at the Asia-Pacific Conference of German Business in Seoul, Boehringer Ingelheim Chairman of the Board of Managing Directors, Shashank Deshpande, highlights the region's growing role
- Boehringer builds on its integrated R&D and manufacturing operations in Japan, a growing presence in China and an expanding network of collaborations and partnerships across the entire region
- Boehringer runs more than 200 clinical trials in Asia-Pacific and partners with some 160 institutions
- Marking 50 years in Korea, Boehringer reaffirms its long-term commitment to life science R&D in the country
Seoul, Korea - Boehringer Ingelheim today highlighted Asia-Pacific's increasing importance in global life science innovation. Speaking at the Asia-Pacific Conference of German Business (APK) 2026 in Seoul, Shashank Deshpande, Boehringer Ingelheim Chairman of the Board of Managing Directors, said that “Asia-Pacific is rapidly gaining importance as a major pillar in global life science innovation”, driving patient access to new medicines and improving animal health and food chain safety and security.
“Predictable and science-friendly policy frameworks that attract investment are essential to improve access to new human and animal health products,” Deshpande said. “As international competition for talent, research and development capabilities and investments is increasing globally, Asia-Pacific is rapidly gaining importance in life science innovation.” He went on to explain: “We draw on Europe's scientific depth, the broad US innovation environment and Asia-Pacific's speed, scale and growing R&D capabilities to drive our global innovation engine. Our ability to integrate technologies and scientific expertise from around the world puts Boehringer in a strong position to deliver breakthrough innovation for the patients and animals we care for.”
Partnering with Asia-Pacific
Boehringer Ingelheim's partnerships in Asia-Pacific span the full pathway from discovery to patient access. In 2025, the company conducted more than 200 clinical studies with more than 160 academic institutions across the ASEAN countries, Japan, Korea, Australia and New Zealand. Its screening programs for chronic kidney disease and heart failure have reached more than 72,000 people in Malaysia, the Philippines and Thailand, with several pilots now being scaled by local governments. In Animal Health, its “Stop Rabies” program has provided more than 65 million vaccine doses for dogs and cats across five Southeast Asian countries since 2022.
“Across Asia-Pacific, we increasingly innovate with the region, not only for it,” said Deshpande. “Progress happens when governments, researchers, healthcare providers and industry work together. This is how ideas move from the lab into clinical practice and successful pilots into national health systems.”
Bridging innovation ecosystems
Boehringer Ingelheim is advancing around 80 projects in its human pharma pipeline alone, with around 50% anchored in external collaborations. Boehringer has operated in Asia-Pacific since establishing its Japanese subsidiary in 1961, where it is one of the only foreign pharmaceutical companies with both R&D and manufacturing capabilities. In 2025, the company invested EUR 300 million in its Yamagata plant to expand its strategic positioning as an export hub for the Asia-Oceania region. Today, there are 65 local clinical studies with more than 1,900 participants, and its 2,280 employees contribute to our global research and manufacturing network.
50 years in Korea, focused on the future
As host of APK 2026, Korea reflects Asia-Pacific's growing strengths in AI-enabled drug discovery, health data and clinical research. Boehringer Ingelheim currently conducts around 50 clinical studies in the country and is expanding its partnerships across Korea's life science ecosystem. Marking 50 years in Korea, the company and Yuhan signed a Memorandum of Understanding on the sidelines of APK 2026, extending their partnership of more than 15 years into clinical and scientific collaboration, as well as patient access.
About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective. Our approximately 54,300 employees serve over 130 markets to build a healthier tomorrow. Learn more at www.boehringer-ingelheim.com.
- 世贸通美国EB5投资移民:美国移民申请新规须注意
- 武汉思澄教育:诚信铸就品牌,荣获AAA级企业信用等级证书
- 全视界 看我的!爱尔眼科ICL全球手术量十连冠·福州爱尔专家见面会圆满举办
- American Eagle正式宣布Lamine Yamal出任全球品牌大使
- 哈曼收购采埃孚高级驾驶辅助系统(ADAS)业务
- 栖作「奇遇小弹垫」上新,重新定义薄床垫
- 当“中餐厅”搬进家,博世T刀双刃侧吸油烟机重塑餐厨社交新场景
- 全球首个AI语言艺术大模型落地海外——优谷走进马来西亚百年华校
- LambdaTest 发布真实设备测试用 Media Injection 功能
- 让通勤值得:来自顶尖 1% 办公场所的启示
- 2025十款降血压血脂品牌红榜揭秘,onstin血活源高强效强势登顶
- 瑞派董事长李守军国际亚洲兽医大会暨展览会开幕致辞: 坚定“走出去”积极“引进来”,深化国际合作,驱动宠物产业实现新飞跃
- YYForce 打造人类、机器人与物联网统一平台,赋能酒店业蓄势迎接超级智能时代
- Julius Meinl小红帽咖啡:打工人午后焕新活力的神器
- 2026年南通钰博装饰材料有限公司打造城市名片与心灵栖息地的完美结合
- 谷医堂中医互联网医院的“科技与狠活”
- 记石家庄市长安区2025年世界读书日(世界版权日)文化惠民活动
- 又一波《浪姐》群像袭来 今年我被“非典型富二代”蒋一侨狠狠惊艳
- 翟文章书法欣赏书法价格
- 企业家家族的健康标配:左手高端医疗险,右手国康私人医生
- 汪喵灵灵亮相亚宠论坛,AI大模型破解异宠医疗资源困局
- Brightcove推出“营销洞察”,为视频营销效果衡量设定新标准
- 中国建筑以AI科技赋能建筑全产业链 打造差异化竞争优势
- 直击公园痛点 系统性迭代进化 华纳文化制定公园5.0标准,让幸福与快乐自然发生
- Bitget 五月报告亮点:期货交易量增长 21%,推动平台跃居全球交易所前三
- 做年轻人的躺平搭子——东呈青猫会为年轻人而生,演绎品牌价值观
- nCino Announces Timing of its First Quarter Fiscal Year 2025 Financial Results Conference Call
- Curia Announces Strategic Refinancing to Support Continued Growth
- 《铁血金盾》震撼上线爱奇艺:卧底警探 铁血缉毒!
- 雄安商务服务中心寻环 XLOOP 新年 赋能情绪与年轻人玩在一起





